Gene therapy is a biomedical technology that introduces exogenous genetic material into appropriate target cells of patients, allowing the exogenous gene to directly act or express target products to treat diseases. Gene therapy products can intervene in gene regulation at the genetic level, overcoming the limitations of traditional small molecule drugs and antibody biologics that only intervene at the protein regulation level. Gene therapy can achieve true "cure the symptoms and root causes" for tumors or genetic diseases.
One of the key aspects of drug development for gene therapy is the pharmacodynamic (PD) evaluation, which measures the biological effects of the gene therapy product on the body. The PD evaluation of gene therapy products requires non-traditional and comprehensive bioanalytical methods to detect the expression and activity of the target gene and its product protein. The bioanalytical methods should also consider the potential immunogenicity and toxicity of the gene therapy product, as well as the biomarkers related to its mechanism of action and clinical efficacy.
The PD evaluation of gene therapy products usually involves the following aspects:
Product protein expression level: The bioanalytical method should be able to accurately detect and quantify the product protein in various biological matrices, such as target tissues, blood, cerebrospinal fluid, vitreous humor, etc. The method should also have high sensitivity and wide dynamic range to cover the possible changes in product protein concentration after gene therapy. The preferred method is immunoassay, which is relatively simple and direct, can quickly prepare or use commercial reagents, and has standardized and automated procedures. The method should also avoid potential interference from truncated or non-functional proteins, endogenous proteins, or binding ligands.
Product protein activity: In addition to the qualitative and quantitative analysis of product protein, some gene therapy products also require the evaluation of product protein activity. The ideal method is enzyme activity assay, which can measure the catalytic function of product protein. The enzyme activity assay can provide additional information on the temporal changes of product protein activity, which may have higher tolerance for analytical variability and smaller dynamic range than protein level analysis. Combining both analyses can improve the biological significance of the data and enhance the resolution of subtle differences between treatment groups. However, compared to protein level analysis, enzyme activity assay usually requires more stringent stability of product protein in patient samples.
Biomarkers: Biomarkers are important for monitoring diagnosis, prognosis, prediction, safety, etc. It is recommended to include biomarker bioanalysis in clinical trial protocols to form a complete bioanalytical data system, which may be more conducive to the marketing application of gene therapy products. For example, gene therapy may cause changes in various biomarkers in serum, such as interleukins (e.g., IL-2, IL-4, IL-8, IL-10), pro-inflammatory cytokines (e.g., IFN-γ, TNF-α), growth factors (e.g., TGF-β), etc.; as well as changes in immune cell number, proportion, phenotype (e.g., CD4+, CD8+ T cells, NK cells, etc.). The challenge of biomarker detection is to design reasonable cytokine panels and immune cell panels, as well as to select suitable bioanalytical platforms.
Gene therapy is a promising field that has great potential for curing various diseases. However, it also poses many challenges for bioanalysis, which requires novel and robust methods to characterize the safety and efficacy of gene therapy products. Bioanalysts need to have sufficient experience and case-by-case strategy to overcome these challenges and provide reliable data for drug development.
